Condition Intervention Phase Clinical trial identifier*
Infectious Diseases      
Influenza virus Influenza DNA vaccine/Trivalent inactivated vaccine Phase I NCT01609998
NCT01498718
NCT01676402
NCT00995982
  Monovalent H5 Influenza DNA vaccine (A Vietnam/1194/2004) Phase I NCT00347529
  Trivalent DNA vaccine (PIA0601) with or without DEI-LT (pPJV2012) Phase I NCT00375206
  VCL-IPT1 and VCL-IPM1 DNA vaccines Phase I NCT00709800
NCT00694213
  Prime-boost with monovalent Influenza subunit virion (H5N1) vaccine followed by H5 DNA vaccine (VRC-AVIDNA036-00-VP) Phase I NCT01086657
NCT00776711
  H1 and H5 Influenza hemagglutinin DNA vaccines Phase I NCT01405885
  Trivalent (A/New Caledonia/20/99, A/Panama/2007/99, B/Jiangsu/10/20) DNA Influenza vaccine Phase I NCT00349037
  Recombinant H7 DNA vaccine administered alone or with monovalent Influenza subunit virion H7N9 vaccine (MIV) Phase I NCT02206464
  DNA-based Influenza vaccine (FVH1) Phase I NCT01587131
  H5 avian Influenza DNA vaccine (VGX-3400X) Phase I NCT01142362
NCT01184976
  H1 Influenza DNA vaccine (VRC-FLUDNA057-00-VP) Phase I NCT00973895
  Influenza DNA vaccine (VRC-FLUDNA047-00-VP) followed by the seasonal Influenza trivalent inactivated vaccine (TIV) Phase I NCT00858611
Hemorrhagic Fever With Renal Syndrome Hantaan/Puumala Virus DNA Vaccine Phase II
Phase I
NCT02116205
NCT01502345
Venezuelan Equine Encephalitis Virus Infection Venezuelan Equine Encephalitis Virus DNA vaccine Phase I NCT01984983
Dengue Dengue-1 pre-membrane/envelope DNA vaccine Phase I NCT00290147
  Tetravalent Dengue vaccine formulated with Vaxfectin® Phase I NCT01502358
Chronic Hepatitis B HBV envelope DNA vaccine (pCMVS2.S) Phase I, Phase II NCT00536627
NCT00988767
  Mixed plasmid DNA (HB-110) vaccine Phase I NCT00513968
  pPDPSC18 DNA vaccine Phase I NCT00277576
  HB110E Hepatitis B DNA vaccine in combination with Entecavir - NCT01813487
  DNA vaccine encoding HBsAg and HBcAg (INO-1800) and a DNA plasmid encoding human IL-12 (INO-9112) Phase I NCT02431312
  VGX-6150 Phase I NCT02027116
HIV HIV clades B and C DNA vaccine Phase II NCT01705223
  HIV gag, pro, RT, env, tat, vpu, and rev DNA vaccine (pGA2/JS2) Phase I NCT00043511
NCT00908323
  Prime-boost with pGA2/JS2 DNA vaccine followed by a modified vaccinia HIV vaccine (MVA/HIV62) Phase I
Phase II
NCT00301184
NCT00820846
  Prime-boost with pGA2/JS7 DNA vaccine followed by a modified vaccinia HIV vaccine (MVA/HIV62) Phase I NCT01378156
  PENNVAX®-GP (gag, pol, env) HIV-1 DNA vaccine and a DNA plasmid encoding human IL-12 Phase I NCT02431767
  PENNVAX®-B (gag, pol, env) HIV-1 DNA vaccine and a DNA plasmid encoding human IL-12 Phase I NCT00991354
  PENNVAX®-B (gag, pol, env) HIV-1 DNA vaccine with or without a DNA plasmid encoding human IL-12 or IL-15 Phase I NCT00775424
NCT00528489
  PENNVAX™-B (gag, pol, env) administered by electroporation Phase I NCT01082692
  Prime-boost with PENNVAX-G DNA (HIV-1 env A, C, and D, and consensus gag plasmids) followed by modified vaccinia HIV vaccine (MVA-CMDR) Phase I NCT01260727
  Prime-boost with HIV-1 DNA Priming Regimens (Nat-B Env, CON-S Env, and Mosaic Env) followed by MVA-CMDR Phase I NCT02296541
  Prime-boost with HIV-1 DNA vaccine (DNA HIVIS) followed by a modified vaccinia HIV vaccine (MVA-CMDR) Phase I NCT01407497
  Prime-boost with env DNA vaccine followed by env recombinant adenovirus (AdV5 and AdV35) Phase I NCT00801697
  Prime-boost with multiclade, multigene HIV DNA vaccine followed by env recombinant adenovirus (AdV5 and AdV35) Phase I NCT00472719
  Prime-boost with multiclade HIV-1 DNA vaccine followed by a multiclade HIV-1 recombinant adenovirus (AdV5) Phase II NCT00865566
  Prime-boost with DNA-HIV-recombinant vaccine (EP-1233) followed by an HIV-recombinant viral vaccine (MVA-mBN32) Phase I NCT00428337
  HIV-1 gag DNA vaccine administered together a DNA plasmid encoding IL-15 Phase I NCT00115960
  HIV-1 DNA vaccine encoding a modified Gag-Pol protein Phase I NCT00009685
  Prime-boost with a DNA vaccine (GEO-D03) followed by a modified vaccinia HIV vaccine (MVA/HIV62) Phase I NCT01571960
  HIV-1 gag DNA vaccine administered together a DNA plasmid encoding IL-12 Phase I NCT00111605
  HIV-1 DNA vaccine encoding the env and rev genes (APL 400-003) Phase I NCT00001538
NCT00002232
NCT00002231
NCT00002350
  HIV-1 gag-pol DNA vaccine (APL-400-047) administered with bupivacaine Phase I NCT00001088
  DNA vaccines encoding HIV clades A, B and C env, clade B rev, clades A and B gag, and clade B RT Phase I NCT01140139
  Prime-boost DNA vaccine encoding multiple HIV-1 proteins (HIV-MAG) with or without a DNA plasmid encoding IL-12 followed by VSV-gag HIV vaccine Phase I NCT01578889
NCT01859325
  HIV DNA vaccine (DNA-HIV-PT123) administered with a gp120 protein vaccine (AIDSVAX®B/E) or HIV vaccine (NYVAC-HIV-PT1 and NYVAC-HIV-PT4) administered with a gp120 protein vaccine (AIDSVAX®B/E) Phase I NCT01799954
  HIV DNA vaccine (DNA-HIV-PT123) administered with a gp120 protein vaccine (AIDSVAX®B/E) Phase I NCT02376582
  Prime-boost with a HIV DNA vaccine (DNA-HIV-PT123) followed by NYVAC HIV protein vaccine (NYVAC-HIV-PT1 and NYVAC-HIV-PT4) Phase I NCT01783977
  DNA vaccine composed of 21 highly specific CTL epitopes (EP HIV-1090) Phase I NCT00054860
NCT00052182
  Prime-boost with a DNA vaccine (pSG2.HIV) followed by ChAdV63-HIV or MVA-HIV after depletion of serum amyloid P component Phase I, Phase II NCT02425241
  HIV-1 vaccine encoding the gag, env, pol, nef, and tat antigens (ADVAX) administered by electroporation Phase I NCT00545987
NCT00249106
  Prime-boost with a DNA vaccine (encoding clade B HIV-1 gag, pol and nef and HIV-1 env glycoprotein from clades A, B, and C) followed by four non-replicating AdV (encoding HIV-1 gag/pol polyproteins from clade B and HIV-1 env glycoproteins from clades A, B, and C) Phase I NCT00109629
NCT00321061
  Prime-boost with a DNA vaccine (encoding clades A, B, and C HIV gag, pol, nef, and env) followed by AdV (encoding gag, pol, and env). Phase I NCT00384787
NCT00270465
  DNA vaccine (GTU-MultiHIV B) followed by a Lipopeptide vaccine (LIPO-5) Phase II NCT01492985
  DNA vaccine encoding gag, pol, vpr, nef, rev, and env (EP HIV-1090) compared with recombinant protein vaccine containing the 18 HIV proteins from pol, vpu, and gag (EP HIV-1043) Phase I NCT00141024
  Multiclade HIV-1 DNA Vaccine (VRC-HIVDNA009-00-VP) Phase I,
Phase II
NCT00071851
NCT00125099
NCT01549470
NCT00047931
  Multiclade HIV-1 DNA vaccine (VRC-HIVDNA009-00-VP) administered with IL-2/Immunoglobulin DNA vaccine Phase I NCT00069030
  Multiclade HIV-1 DNA vaccine (VRC-HIVDNA016-00-VP) Phase I NCT00089531
  Prime-boost with a multiclade HIV-1 DNA vaccine (VRC-HIVDNA016-00-VP) followed by AdV vaccine (VRC-HIVADV014-00-VP) Phase I NCT01054872 NCT01386489
  Prime-boost with a multiclade HIV-1 DNA vaccine (VRC-HIVDNA009-00-VP) followed by AdV vaccine (VRC-HIVADV014-00-VP) Phase I NCT00270218
  HIV-1 DNA vaccine expressing gag, pol, nef, and env (VRC-HIVDNA006-00-VP) Phase I NCT00045838
  B clade DNA vaccine encoding a multi-HIV antigen consisting of a synthetic fusion protein built up by full-length polypeptides of Rev, Nef, Tat, p17 and p24 with more than 20 Th and CTL epitopes of protease, RT and gp160  (GTU®). Phase I NCT02075983
  HIV-1 multi-envelope DNA vaccine (EnvDNA) Phase I NCT00187148
  Prime-boost with a multigene DNA vaccine consisting of two plasmids expressing an HIV-1 subtype C polyprotein (Gag, RT, Tat, Nef) and an HIV-1 subtype C truncated Env (SAAVI DNA-C2) followed by a recombinant MVA vaccine expressing the same immunogens (SAAVI MVA-C). Phase I NCT00574600
  DNA vaccine encoding a gag, pol and nef polypeptide and the gp140 env followed by MVA expressing gag, pol, nef and gp120 Phase I NCT01922284
Plasmodium falciparum Malaria Polyepitope DNA Vaccine Phase I NCT01169077
  Prime-boost with a DNA vaccine followed by AdV encoding Circumsporozoite Protein and Apical Membrane Antigen 1 Phase I NCT00870987
Herpes Simplex Virus Type 2 (genital herpes) pPJV7630 HSV-2 DNA vaccine Phase I NCT00274300
NCT00310271
  Plasmid DNA vaccine encoding one or two HSV-2 proteins (VCL-HM01 and VCL-HB01) Phase I, Phase II NCT02030301
Cancer      
Head and Neck Squamous Cell Cancer DNA plasmids encoding E6 and E7 proteins of HPV 16 and HPV 18 (VGX-3100) administered with DNA plasmid encoding human IL-12 (INO-9012) Phase I NCT02163057
Aerodigestive Malignancies DNA plasmid encoding HPV 6 proteins (INO-3106) administered with DNA plasmid encoding human IL-12 (INO-9012) Phase I NCT02241369
Cervical Cancer HPV16 E6/E7, HPV18 E6/E7 DNA Vaccine Phase II NCT01304524
  pNGVL4a-CRT/E7 DNA vaccine - NCT00988559
  DNA plasmids encoding E6 and E7 proteins of HPV 16 and HPV 18 administered with DNA plasmid encoding human IL-12 Phase I,
Phase II
NCT02172911
  DNA plasmids encoding E6 and E7 proteins of HPV 16 and HPV 18 (VGX-3100) Phase I NCT00685412
NCT01188850
  GX-188E Phase II NCT02139267
Cervical Cancer, Precancerous Condition pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine Phase I,
Phase II
NCT00121173
NCT00788164
  pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine with or without topical Imiquimod Phase I NCT00788164
Breast Cancer Personalized polyepitope DNA vaccine Phase I NCT02348320
Metastatic Breast Cancer Mammaglobin-A DNA vaccine Phase I
Phase I
NCT00807781
NCT02204098
Breast and Ovarian Cancers DNA vaccine encoding the HER-2/Neu intracellular domain (pNGVL3-hICD) admixed with GM-CSF Phase I NCT00436254
Ovarian Epithelial Cancer pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine Phase I NCT01322802
Melanoma Xenogeneic Tyrosinase DNA Vaccine Phase I NCT00471133
  gp75 DNA vaccine Phase I NCT00034554
  gp100 DNA vaccine Phase I NCT00104845
NCT00398073
  Human tyrosinase DNA vaccine
Mouse tyrosinase DNA vaccine
Phase I NCT00698100
NCT00680589
  Synchrovax®pSEM Vaccine (MKC1106-MT) Phase I, Phase II NCT00033228
Lymphoma Xenogeneic CD20 DNA vaccine Phase I NCT00561756
Lymphoplasmacytic Lymphoma Lymphoma immunoglobulin derived scFV-chemokine DNA vaccine Phase I NCT01209871
Prostate Cancer DNA vaccine encoding androgen receptor ligand-binding domain (AR LBD) with or without GM-CSF Phase I NCT02411786
  DNA vaccine encoding the rhesus prostate specific antigen (rhPSA) Phase I, Phase II NCT00859729
  DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) with recombinant GM-CSF Phase II
Phase I
NCT01341652
NCT00582140
  Sipuleucel-T with or without prostatic acid phosphatase DNA (pTVG-HP) Booster Vaccine Phase II NCT01706458
  pTVG-HP DNA vaccine with rhGM-CSF Phase II NCT00849121
Neuroendocrine Carcinoma IL-12 DNA vaccine Phase II NCT01440816
Pancreatic Cancer Vascular endothelial growth factor receptor 2 (VEGFR-2) DNA vaccine (VXM01) Phase I NCT01486329
Kidney Cancer Human prostate-specific membrane antigen DNA vaccine Phase I NCT00096629
Others      
Allogeneic Hematopoietic Cell Transplant Cytomegalovirus therapeutic DNA vaccine (ASP0113) Phase II NCT01903928
Allergic Rhinoconjunctivitisto Japanese red cedar DNA vaccine encoding the CryJ2- gene fused to the lysosomal associated membrane protein (CryJ2 -DNA-LAMP) Phase I NCT01707069
Seasonal Allergic Rhinitis Amb a 1 ImmunostimulatoryOligodeoxyribonucleotide Conjugate (AIC) Phase II NCT00346086
* www.clinicaltrials.gov
HBV: Hepatitis B Virus; HBsAg: Hepatitis B Surface Antigen; Th: T Helper; CTL: Cytotoxic T Lymphocyte; IL: Interleukin; AdV: Adenovirus; ChAdV: Reverse Transcriptase; HPV: Human Papiloma Virus.
Table 3: Human clinical trials involving DNA vaccines.